Welcome to our dedicated page for Genenta Science Spa SEC filings (Ticker: GNTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genenta Science S.p.A. filings document a foreign private issuer reporting on Form 6-K, with disclosures incorporated by reference into its Form F-3 registration statement when specified. The record covers material events, shareholder voting matters, capital-structure updates, operating and financial results, and clinical or regulatory disclosures for its biotechnology platform and Temferon program.
The filings also document governance and corporate-structure actions, including the approved expansion of the company’s corporate purpose to sectors covered by Italian Golden Power legislation, board changes, listing-compliance notices, material agreements, and decisions to streamline subsidiaries and finance-function arrangements as Genenta pursues an Italy- and Europe-focused industrial aggregator strategy.
Genenta Science S.p.A. completed its acquisition of the remaining 80.5% equity ownership of A.T.C. S. from the existing A.T.C. shareholders. This follows an earlier Investment Agreement and is governed by an Amendment Agreement dated May 25, 2026, approved by the board on May 18, 2026.
The transaction was finalized before an Italian notary on May 29, 2026, making A.T.C. fully owned by Genenta. The parties remain subject to provisions such as a lock-up period, put option, and call option, as outlined in the A.T.C. Amendment Agreement, which is filed as Exhibit 10.1.
Genenta Science S.p.A. has approved the termination of its amended and restated license agreement with Ospedale San Raffaele, which covered certain technology and intellectual property rights licensed to the company. The termination will end the licenses and option rights granted under the agreement, except for surviving and wind-down provisions and any accrued obligations.
The company does not expect any material termination fee or penalty beyond obligations already accrued. Management reached this decision after reviewing strategic priorities and plans to redirect resources to ongoing business and strategic initiatives. Genenta will continue to support and monitor its active glioblastoma multiforme clinical trial, where two patients are currently under observation.
Genenta Science S.p.A. shareholders have filed a joint Schedule 13D reporting a coordinated stake in the company. Eleven investors, including individuals and Italian investment companies, report beneficial ownership of 5,433,910 Ordinary Shares and ADS, representing about 23.0% of shares and 31.5% of total voting power as of March 19, 2026.
The group was formed under a Shareholders' and Joint Filing Agreement dated May 4, 2026, with a five‑year term. They state their goal is to promote stability in Genenta’s biotech-focused strategic direction and to oppose recent amendments expanding the corporate purpose to broadly reference Italian “Golden Power” sectors. Certain members have already brought court proceedings in Milan challenging these corporate changes.
The shareholders plan to coordinate voting at shareholders’ meetings, including presenting a joint slate for the board of directors and statutory auditors, and indicate they are not seeking to acquire additional shares in connection with these objectives. They report having invested approximately $18.6 million (about €15.9 million) in Genenta over time using personal or working capital.
Genenta Science S.p.A. reported that Chief Executive Officer Pierluigi Paracchi received a grant of stock options for 100,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
According to the grant terms, the options vest in equal monthly installments over three years beginning March 30, 2026, meaning the award becomes exercisable gradually rather than all at once. After this grant, Paracchi holds stock options covering 100,000 ADSs directly under this award.
Genenta Science S.p.A. is closing its wholly owned U.S. subsidiary, Genenta Science, Inc., after a strategic review and a decision to focus on building an industrial aggregator in Italy and Europe. The closure aims to streamline operations, reduce costs, and focus on core markets.
The closure is expected to be substantially completed by July 31, 2026 and is anticipated to result in minimal one-time charges, with no material adverse effect on the company’s overall financial position or liquidity. Former CFO Richard B. Slansky will move from employee to a 12‑month consulting role effective June 1, 2026, continuing as principal financial and accounting officer under a binding consulting agreement that provides fees, healthcare reimbursements, and potential performance-based or equity compensation.
Genenta Science is accelerating its transformation into a biotech, defense, aerospace, and national‑security industrial consolidator by signing definitive agreements to acquire majority ownership of Sòphia High Tech, an Italian aerospace and defense engineering and manufacturing company.
Genenta expects to fund a total of €6.0 million in two tranches. The first tranche combines payments to founders and a €3.25 million reserved capital increase, giving Genenta a 19.9% stake in Sòphia HT; completion of a second tranche would raise its stake to 51%, with an additional potential €0.5 million earnout tied to EBITDA milestones.
Sòphia HT reported approximately €6.29 million in 2024 revenue and other operating income and €0.96 million EBITDA, and preliminarily expects about €8 million in 2025 sales. Over the medium term, it currently targets roughly doubling its 2024 revenue by 2027 and expanding its workforce from 44 to about 70 employees.
Genenta Science S.p.A. has received a Nasdaq notice that its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2). The closing bid stayed below this level from February 26 to April 9, 2026.
The company retains its listing for now and has 180 days, until October 7, 2026, to regain compliance. If it qualifies under other Nasdaq Capital Market standards, it may receive an additional 180-day period, potentially using a reverse stock split. Management is evaluating options but cannot assure successful or timely compliance.
Genenta Science S.p.A. reported that its CMO & Head of Development, Francesco Galimi, received a grant of stock options covering 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026. Following this grant, Galimi holds stock options for 20,000 ADS directly, reflecting a compensation-related award rather than an open-market transaction.
Genenta Science S.p.A. director Giacomoantonio Paracchi reported a compensation-related grant of stock options. On March 30, 2026, he was awarded options covering 20,000 American Depositary Shares at an exercise price of $0.63 per share, expiring on December 31, 2035.
The options vest in equal monthly installments over one year beginning March 30, 2026, aligning the award with ongoing service. Following this grant, Paracchi holds 20,000 stock options directly.
Genenta Science S.p.A. director Sharei Armon received a grant of stock options for 20,000 American Depositary Shares. The options have an exercise price of $0.63 per share and expire on December 31, 2035. They vest in equal monthly installments over one year beginning March 30, 2026.